Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Universal HBV vaccination is one of the most effective tools to prevent liver cancer, yet only 30% of U.S. adults are vaccinated, and birth-dose rates are falling. With 2.4 million Americans living with chronic HBV — 70% unaware — experts are sounding the alarm. System-level disruptions like Medicaid cuts and rural hospital closures are making the universal birth dose more critical than ever.
The hepatitis B virus (HBV) vaccine holds a unique distinction: it was the world's first anti-cancer vaccine. Yet despite its proven ability to prevent liver cancer, vaccination rates in the U.S. remain alarmingly low — and they're getting worse. Only 30% of American adults are vaccinated against HBV, and birth-dose rates have dropped by more than 10% in the past two years, raising serious public health concerns.
Up to 2.4 million Americans are currently living with chronic HBV infection, a leading risk factor for liver cancer. The stakes are high — 1 in 4 people with chronic HBV will develop cirrhosis, liver cancer, or liver failure, and the 5-year survival rate for liver cancer is just 22%. Compounding the crisis, 70% of those infected don't even know it.
Healthcare access barriers — including Medicaid eligibility changes, ACA affordability issues, and rural hospital closures — are fragmenting prenatal care and increasing the risk that newborns won't receive the protective birth dose.
By the Numbers:
Why it matters: HBV vaccination is a rare, proven tool that prevents cancer — but its impact depends on universal uptake. As systemic healthcare disruptions erode access to prenatal and newborn care, the universal birth dose serves as a critical safety net, especially for communities disproportionately burdened by HBV and liver cancer.
